Literature DB >> 24848755

Tofogliflozin: first global approval.

Raewyn M Poole1, Jennifer E Prossler.   

Abstract

Tofogliflozin (Apleway(®), Deberza(®) [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24848755     DOI： 10.1007/s40265-014-0229-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  16 in total

1.  A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.

Authors:  S Ikeda; Y Takano; O Cynshi; R Tanaka; A D Christ; V Boerlin; U Beyer; A Beck; C Ciorciaro; M Meyer; T Kadowaki
Journal:  Diabetes Obes Metab       Date:  2015-08-20       Impact factor: 6.577

2.  Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.

Authors:  Manfred Zell; Christophe Husser; Olaf Kuhlmann; Dietmar Schwab; Takahide Uchimura; Tomonori Kemei; Kosuke Kawashima; Mizuki Yamane; Axel Pähler
Journal:  Xenobiotica       Date:  2013-09-27       Impact factor: 1.908

3.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

4.  In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.

Authors:  Koji Yamaguchi; Motohiro Kato; Masayuki Suzuki; Hitoshi Hagita; Maiko Takada; Miho Ayabe; Yoshinori Aso; Masaki Ishigai; Sachiya Ikeda
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

5.  A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.

Authors:  Dietmar Schwab; Agnes Portron; Zoe Backholer; Berthold Lausecker; Kosuke Kawashima
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

6.  Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Authors:  Takumi Nagata; Masanori Fukazawa; Kiyofumi Honda; Tatsuo Yata; Mio Kawai; Mizuki Yamane; Naoaki Murao; Koji Yamaguchi; Motohiro Kato; Tetsuya Mitsui; Yoshiyuki Suzuki; Sachiya Ikeda; Yoshiki Kawabe
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

7.  Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.

Authors:  Yukio Tanizawa; Kohei Kaku; Eiichi Araki; Kazuyuki Tobe; Yasuo Terauchi; Kazunori Utsunomiya; Yasuhiko Iwamoto; Hirotaka Watada; Wataru Ohtsuka; Daisuke Watanabe; Hideki Suganami
Journal:  Expert Opin Pharmacother       Date:  2014-02-11       Impact factor: 3.889

8.  SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Authors:  Edward C Chao
Journal:  Clin Diabetes       Date:  2014-01

Review 9.  SGLT inhibitors in management of diabetes.

Authors:  Abd A Tahrani; Anthony H Barnett; Clifford J Bailey
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-13       Impact factor: 32.069

10.  Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Authors:  Jiwen Jim Liu; TaeWeon Lee; Ralph A DeFronzo
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461
View more
  28 in total

Review 1.  Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 2.  Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 3.  The renal effects of SGLT2 inhibitors and a mini-review of the literature.

Authors:  Vasileios Andrianesis; Spyridoula Glykofridi; John Doupis
Journal:  Ther Adv Endocrinol Metab       Date:  2016-11-11       Impact factor: 3.565

4.  Diabetes market grows ever more crowded.

Authors:  Kunj Gohil; Devin Enhoffer
Journal:  P T       Date:  2014-12

Review 5.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

6.  Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology.

Authors:  Anzhu Wang; Zhendong Li; Sun Zhuo; Feng Gao; Hongwei Zhang; Zhibo Zhang; Gaocan Ren; Xiaochang Ma
Journal:  Front Cardiovasc Med       Date:  2022-05-23

Review 7.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

8.  Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

Authors:  Elza Muscelli; Brenno Astiarraga; Elisabetta Barsotti; Andrea Mari; Freimut Schliess; Leszek Nosek; Tim Heise; Uli C Broedl; Hans-Juergen Woerle; Ele Ferrannini
Journal:  Diabetologia       Date:  2015-12-24       Impact factor: 10.122

Review 9.  Dapagliflozin for the treatment of type 2 diabetes: a review of the literature.

Authors:  Mujahid A Saeed; Parth Narendran
Journal:  Drug Des Devel Ther       Date:  2014-12-10       Impact factor: 4.162

10.  Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.

Authors:  Kazunori Utsunomiya; Naoki Shimmoto; Masayuki Senda; Yuji Kurihara; Ryoji Gunji; Hiroyuki Kameda; Masahiro Tamura; Hanako Mihara; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2016-04-24       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.